

**Dr. Nassos Alevizopoulos** was born in 1967 in Athens, Greece. While working on the diploma thesis in enzyme biochemistry, he received a pre-graduate scholarship from the European Molecular Biology Organization of Heidelberg, Germany, to later graduate with a Diploma in Biology from the University of Athens. Nassos earned a PhD in Biology from the University of Lausanne in Switzerland, where his innovative work on the signal transduction of the cell growth regulator TGFβ and the pro-inflammatory cytokine TNFα received the 1997 Brunner Prize of Excellence (best of 181 doctorates.) He then did postdoctoral research in Neurobiology at the Friedrich-Miescher Institute (now part of Novartis Institute of Biomedical Research) of Basel, Switzerland. Following a year as a Clinical Research Associate with Quintiles Inc. in Germany, Nassos was accepted to earn an MBA in Strategy & Finance at the Lausanne Business School, graduating second in his class. His MBA consulting project was with Biolens SA of France, while he subsequently co-founded the biotechnology transfer consultancy Epektasis SA. Having served as a Medical Microbiologist of the Greek army for about a year, Nassos joined Novartis Hellas where he worked as Business Planning and Analysis Manager for three years (dignified as top 7 performer in Region Europe, 2004). He was then named Vice-President & CEO of Bionova Ltd., a Greek PR consultancy with biotechnology transfer activities. As a Senior Vice President of Drug Development & Licensing for Regulon Inc, a leading Greek biotech company with operations in the United States, Nassos directed a clinical team to earn an Orphan Drug designation for a liposomal cisplatin (Lipoplatin) in pancreatic cancer by European Medicines Agency. He also negotiated a termsheet of US\$50M for a global Lipoplatin outlicensing deal with a \$6B pharmaceutical company. Following a term as Chief Executive Officer of Biomedcode Hellas SA, a leading preclinical Contract Research Organization offering world-class mouse models for autoimmune diseases, in 2010 Nassos co-founded Dyonmed S.A., a start-up company active in the Point of Care & Companion Diagnostics of the Medical Devices Industry. Nassos speaks fluently English, German and French and gets around in Italian; he has taught over 3,000 hours of academic classes and is the author of four publications in scientific, peer reviewed journals and of various articles in newspapers & periodicals. Nassos consults with financial & industrial parties on various aspects of biopharmaceutical industry activities such as fundraising, financing rounds, industry outlooks, drug development, corporate development etc. In his spare time, he enjoys basketball and the company of his wife and son.